## AFL: AFLAC Incorporated - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 2.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($106.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Who Owns Aflac? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20251212T130732 | Bullish | Relevance: 100%
- Aflac (NYSE: AFL), a major supplemental insurance provider, is primarily owned by large institutions seeking stable earnings and consistent cash flow. Recent institutional and hedge fund activities indicate sustained confidence in Aflac's long-term stability, with some firms significantly increasing their holdings. Insider trades have been modest, suggesting no major shift in sentiment from leadership.

**2. A new career and a shared mission**
- Source: Aflac Newsroom | 20251212T160800 | Bullish | Relevance: 100%
- Brittany Smith, an Aflac agent, and her husband Brandon, founded the All Heart Gunner Foundation in memory of their son, Gunner, to support families affected by pediatric brain cancer. Brittany discovered Aflac's similar mission to provide financial support during challenging times and became an agent, later integrating Aflac's My Special Aflac Duck program into her foundation's offerings. Aflac has contributed nearly $200 million to pediatric cancer and blood disorder research and treatment, distributing over 41,000 My Special Aflac Ducks to patients.

**3. Axa S.A. Decreases Stock Position in Aflac Incorporated $AFL**
- Source: MarketBeat | 20251211T080748 | Neutral | Relevance: 100%
- Axa S.A. significantly reduced its stake in Aflac Incorporated by 38.9% in the second quarter, selling over 93,000 shares. This move aligns with a trend of insider selling, as company executives sold shares totaling nearly $3 million in the last quarter. Despite the decrease in institutional and insider holdings, Aflac increased its quarterly dividend and analysts maintain a consensus "Hold" rating for the stock.

**4. Federated Hermes Inc. Purchases 287,362 Shares of Aflac Incorporated $AFL**
- Source: MarketBeat | 20251210T140748 | Bullish | Relevance: 100%
- Federated Hermes Inc. significantly increased its stake in Aflac Incorporated by 6,692.2% in Q2, acquiring an additional 287,362 shares and holding a total of 291,656 shares valued at $30.76 million. Aflac's board has approved a 100 million share repurchase plan and raised its quarterly dividend, reflecting confidence in the company's value. Institutional ownership of Aflac stands at 67.44%, while some insiders have recently sold shares.

**5. Honoring 30 Years of Support for Families Facing Childhood Cancer and Blood Disorders**
- Source: CSRwire | 20251213T000747 | Bullish | Relevance: 100%
- Aflac Incorporated is celebrating 30 years of unwavering support for families confronting childhood cancer and blood disorders. What started in 1995 with a $3 million gift has evolved into nearly $200 million in contributions, establishing the Aflac Cancer and Blood Disorders Center as one of the largest pediatric hematology/oncology programs in the country. The company's commitment, initiated by Chairman and CEO Dan Amos, emphasizes comprehensive care, research funding, and emotional support for patients and their families.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-17 | Morgan Stanley | $118 | $113 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-17 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.10M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Japan Post Holdings : 10.0% (0.0%)
- Vanguard Group Inc: 9.6% (-0.8%)
- Blackrock Inc.: 7.4% (+0.1%)
- State Street Corpora: 4.6% (+0.1%)
- Wells Fargo & Compan: 2.1% (-24.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +4.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Quality metrics strong (margin 24%). Balance sheet: strong liquidity (48.2x). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $58.9B |
| Beta | 0.66 |
| 52W Range | $96.95 - $115.84 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 14.9 |
| Current P/E | 14.5 |
| YoY Growth | -2.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -2.4% to 2.4% (+4.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.6pp (needs >3.0% for momentum thesis). MRS_5 at 2.9% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 51. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.37% (CS: 57) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | -0.16 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.031x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $110.05
- **Stop Loss:** $106.71 (3.0% risk)
- **Target:** $113.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 359
- **Position Value:** $39,507.95
- **Portfolio %:** 39.51%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-04 (Est: $1.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $2.49 | +40.2% |
| 2025Q2 | $1.71 | $1.78 | +4.3% |
| 2025Q1 | $1.67 | $1.66 | -0.8% |
| 2024Q4 | $1.62 | $1.56 | -3.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*